Amarin's stock surges after raised revenue outlook, increased commercial expansion of VascepaMarket Watch • 07/02/19
Upon Vascepa Expanded Label, The Landscape For Cardiovascular Disease Would Greatly ChangeSeeking Alpha • 06/12/19
3 Top Mid-Cap Stocks to Buy Right Now: Amarin, Axon Enterprise & Royal GoldThe Motley Fool • 05/30/19
FDA agrees to fast-track review of Amarin's prescription strength fish oil pill for heart patientsCNBC • 05/29/19
This Biotech Stock Rocketed Near A Buy Point On Speedy Drug ReviewInvestors Business Daily • 05/29/19
Amarin's Cardiovascular Fish Oil Pill May Hit Market Sooner: FDA Accords Priority Review DesignationBenzinga • 05/29/19